Xeris Biopharma Inc. (XERS)
NASDAQ: XERS
· Real-Time Price · USD
8.07
0.22 (2.80%)
At close: Sep 26, 2025, 11:06 AM
2.80% (1D)
| Bid | 5.79 |
| Market Cap | 1.3B |
| Revenue (ttm) | 246.03M |
| Net Income (ttm) | -32M |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -40.37 |
| Forward PE | 32 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 8.09 |
| Volume | 343,725 |
| Avg. Volume (20D) | 2,476,071 |
| Open | 7.92 |
| Previous Close | 7.85 |
| Day's Range | 7.87 - 8.15 |
| 52-Week Range | 2.69 - 8.35 |
| Beta | 0.91 |
| Ex-Dividend Date | n/a |
About XERS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol XERS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for XERS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsXeris Biopharma Inc. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+20.22%
Xeris Biopharma Holdings shares are trading higher...
Unlock content with
Pro Subscription
3 months ago
-7.92%
Xeris Biopharma Holdings shares are trading lower. The company released Its strategy for long-term growth and value creation at 2025 analyst & investor day.
1 month ago · seekingalpha.com
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call TranscriptXeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Comm...
1 month ago · fool.com
Xeris (XERS) Q2 Revenue Jumps 49%Xeris (XERS) Q2 Revenue Jumps 49%
